What is Sales and Marketing Strategy of Indoco Company?

The primary domestic channel is a 2,400-strong field force organized into strategic business units focused on key therapeutic areas. This team directly promotes to over 300,000 medical practitioners and covers 80,000 retail pharmacy stockists, contributing to 72% of its FY2024 domestic revenue of INR 14.5 billion.

The company strategically augmented its DTI channel, securing tenders with government hospitals and private hospital chains. This key accounts management channel now accounts for nearly 15% of domestic sales, showcasing a successful market expansion strategy in India.

For its API and contract manufacturing divisions, sales are driven by a dedicated B2B team leveraging long-term supply agreements. This approach with global pharma majors forms a core part of the company's Indoco business development and B2B sales model.

Internationally, the company utilizes a mix of wholly-owned subsidiaries and a network of in-country distributors across over 55 countries. Exports contributed 28% to total revenue in FY2024, with a strategic shift towards higher-regulation markets like the US, where it filed 5 ANDAs in the first half of 2025.

The three-pillar philosophy underpins the entire Indoco marketing strategy. It communicates a steadfast commitment to robust R&D, proven product efficacy, and unparalleled customer support, directly addressing the needs of its B2B sales model.

A cleaner, modern logo and science-forward aesthetic have been rolled out across all collateral. Stringent brand guidelines and a centralized marketing operations team ensure absolute consistency in all communications.

The brand positioning specifically targets specialist doctors like pulmonologists and ophthalmologists, plus institutional procurement managers. This focus allows for highly tailored promotional tactics and customer acquisition efforts.

The company's key differentiator is offering novel generics and complex formulations, such as sterile ophthalmic products and inhalers. This USP leverages its specialized manufacturing expertise and 15 USFDA-approved facilities as a core credibility marker.

This landmark initiative launched Indoco's respiratory franchise with the primary objective of securing a 5% market share for Indofloxacillin. The campaign creatively highlighted the product's superior bacterial eradication rates to differentiate it in a competitive market.

This multi-year campaign focuses on deepening engagement within the ophthalmic sector through large-scale corporate social responsibility efforts. It partners with over 50 key opinion leaders to conduct free screening camps, directly linking patient diagnosis to prescription.

The 'Breathe Free' campaign leveraged a multi-channel approach, deploying a 500-strong dedicated sales force and digital detailing. It utilized KOL-led webinars attracting over 10,000 registrations and targeted journal ads to ensure comprehensive market coverage.

The campaigns delivered exceptional returns, with 'Breathe Free' capturing a 4.8% market share in ten months and generating an estimated INR 900 million in new revenue. 'Clear Vision Mission' has screened over 150,000 patients, driving a 12% prescription uplift.